New CEO appointed, existing CEO steps aside to focus on MD role

Ceo ResignedCeo Appointed ExternalManagement Changes View source PDF Explain this filing

BLISSGVS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.8%Reaction day

₹504.00

prior close

₹505.95

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%-3.0% vs market

Pharmaceuticals peers, median of 164sector-0.5%-2.3% vs sector

On the reaction day the stock moved 3.0 pts less than Nifty Microcap 250 and 2.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.7

10m

+1.4

15m

+0.7

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.8+0.2-3.0-0.5-2.3

Next day

+0.6-0.5+1.1-0.7+1.3

+0.9-2.5+3.4-1.7+2.6

+4.5-0.6+5.2-1.3+5.9

+4.2+0.7+3.4-0.5+4.6

+5.2+0.9+4.3+0.2+4.9

+2.2+0.5+1.7+0.4+1.7

15d

-9.4-0.2-9.2-1.4-8.0

-2.4+2.9-5.3-1.4-1.0

+37.5+5.0+32.5+1.2+36.3

+35.5+3.7+31.8+0.4+35.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Bliss GVS Pharma Board has approved Mr. Rahul Adakmol (ex-Bharat Serums, Dr. Reddy's, Reliance) as CEO effective July 15, 2026. Current CEO Mr. Narsimha Kamath steps aside from CEO role on July 14, 2026 but continues as Managing Director. Mr. Santosh Parab joins as Non-Executive Non-Independent Director.

Likely market impact

Smooth leadership transition. Incoming CEO brings 22 years of pharma CXO experience. Continuity assured as outgoing CEO stays as Managing Director.